Enveric Biosciences (NASDAQ: ENVB) announced new preclinical data supporting the non-hallucinogenic profile of its lead drug candidate, EB-003, according to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE